HF1220

HF1220 is a second-generation neuroprotective small molecule series originally developed by the UK-based biotechnology company Hunter-Fleming. The compound series was acquired by Newron Pharmaceuticals in 2008 as part of a broader portfolio of Central Nervous System (CNS) therapies. HF1220 was designed to provide neuroprotection in various CNS pathologies, potentially building upon the chemical scaffolds of earlier candidates like HF0220. However, following the acquisition, HF1220 remained in the discovery or early preclinical phase and was not advanced into clinical trials by Newron. Consequently, specific details regarding its molecular target, mechanism of action, and precise therapeutic indications remain undisclosed in the public domain.